NYSE:TEVA
Teva Pharmaceutical (TEVA)
34.25
+0.03 (0.09%)
as of Jun 25, 2026, 4:22:07 pm Market Open.
69 watching
Financials 
Technical Analysis 0
Investor Insights
Jun 25, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Teva Pharmaceutical has shown significant improvement in its stock performance, with a notable increase of 264% since the beginning of 2023 under the leadership of its current CEO. Despite the challenges posed by the rising competition in the generic market, particularly for GLP drugs, the demand for these products remains robust. Innovations in drug formulations, such as pill-shaped GLPs, suggest a potential for future growth, yet experts highlight concerns about Teva's innovative capabilities. The company has been experiencing strong accumulation in recent months, breaking through key price resistance levels. Analysts project a price target of $34.50, though Teva currently does not offer dividends.
Consensus
Positive
Valuation
Undervalued
Similar
Pfeizer,PFE
BUY
Most of their drugs are generic. #1 drug is a blockbuster for MS but competition came out with a drug that had good results. Only trades at 10X earnings and has fast growth. Missed its last quarter giving an opportunity to buy at a 20% discount. With an 8 to 12 month time horizon you should do well.
Barry SchwartzOwned
biotechnologypharmaceutical
DON'T BUY
Generic drugs. Has had great success over time taking drugs that are coming off patent and reformulating them. Have had a couple of hiccups in the last year or so in getting new drugs approved. Have a couple of non-generic drugs that are now being challenged by generics. Have missed a couple of estimates in a row. Prefers Perrigo (PRGO-Q).
biotechnologypharmaceutical
TOP PICK
Forth quarter earnings and guidance were not what the analysts were looking for and the stock dropped. Thinks they will earn about $5/share in 2011. Significant free cash flow, double digit growth, best pipeline of any of the generic manufacturers. Very, very shareholder friendly. 25% discount to its piers.
Barry SchwartzOwned
biotechnologypharmaceutical
COMMENT
Sold half his position when it was higher. Really 2 companies. Biggest part is generics. They are the biggest manufacturer globally. A lot of patented drugs will become invalid and they will grow because of it. They are also a pharmaceutical because they have a few drugs. One of them is an MS drug and a large part of their profits. It too is possibly coming up for generic competition, which has held the stock back but this is an opportunity. Probably won’t go any where for a little while. (See Top Picks.)
Norman LevineOwned
biotechnologypharmaceutical
BUY
Loves the generic drug theme, which is a theme that will continue over the next couple of years as governments continue to cut health care coasts. Good growth.
Karl BergerOwned
biotechnologypharmaceutical
COMMENT
PAST TOP PICK
HOLD
Has owned for quite some time. Likes outlook for generic drug companies. They also have some of the their own drugs. There are competing drugs coming out and could be so-so for them. He sold half a couple of months ago. Likes health care in general: valuations are low and dividends are growing and there will be more demand for health-care in the US.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
World leader in generic drug manufacturing. Significant operations in Europe and the US. Made a couple of good acquisitions. Will benefit when other companies drugs come off patent.
Tony DemarinOwned
biotechnologypharmaceutical
TOP PICK
Primarily a generic drug manufacturer. Market has overreacted with the challenge it is facing with from a competitor on one of its branded drugs. 1.5% yield.
Karl BergerOwned
biotechnologypharmaceutical
DON'T BUY
Global leader with about 60% of revenues from US. Generics have recently under performed because of regulatory changes that are squeezing profitability. Generics will continue to expand market share. Acquisitions can take time for results to show in the numbers. Trading below 200 day moving average. Would prefer to see if trading above $60.
biotechnologypharmaceutical
HOLD
Owns half as much as he used to. Worried about their biggest non-generic product. It’s an MS drug with a lot of controversy.
Norman LevineOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
